Our study on #mRNA vax in #SARSCoV2 naive/recovered individuals is up on medRxiv! Massive team effort btw/ @EJohnWherry lab + others @Penn_IFI to profile both antibodies & antigen-specific memory B cells following 1st/2nd doses. bit.ly/3rlfhwO. Full tweetorial below 💉🧵 
1) Consistent w/ what others (e.g. @florian_krammer) have shown: COVID-experienced folks don’t have an increase in antibodies after 2nd dose… clear benefit for people who are COVID-naive
2) We also find the same pattern for antigen-specific memory B cells… COVID-experienced folks have an increase in spike+ and RBD+ memory cells after the first dose, but then plateau w/ no increase in frequency or class switching after the second dose
3) How about other clinical/demographic factors? Age appears to be an important determinant of post-boost memory B cell response (antibodies also trend down, but seem more resilient). Worth noting that regardless of age, everybody is still over pre-vaccine baseline levels
4) For the immunology nerds out there - we also show that taking a snapshot of just antibody levels post-boost is not a good predictor of memory cells. And baseline memory cells in SARS-CoV2 recovered folks correlate strongly with antibody recall responses post-vax
Key take-home messages: 1) SARS-CoV2 recovered people don’t benefit from the 2nd dose by multiple parameters. Might be ok to skip/delay 2nd dose. 2) Age is something to keep an eye on… 3) Memory is important! Especially w/ variants that might escape initial antibody responses
Check out the manuscript for a full analysis/discussion of these points. We should have some more data coming soon! And again, massive thanks to all authors and collaborators @s_apostolidis @markmpainter @divijmathew @Bad2theBeaker @SCOTTeHENSLEY @BettsLab + others @Penn_IFI
• • •
Missing some Tweet in this thread? You can try to
force a refresh
